Caprion Identifies Protein Biomarkers for Predicting Patient Response to New Hepatitis C Drug

The company said that the biomarkers were correlated with sustained viral response or viral cure in response to a combined treatment of pegylated-interferon, ribavirin, and telaprevir, a drug candidate for hepatitis C.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.